Heart failure leads to altered β2-adrenoceptor/cyclic adenosine monophosphate dynamics in the sarcolemmal phospholemman/Na,K ATPase microdomain.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Oxford Journals Country of Publication: England NLM ID: 0077427 Publication Model: Print Cited Medium: Internet ISSN: 1755-3245 (Electronic) Linking ISSN: 00086363 NLM ISO Abbreviation: Cardiovasc Res Subsets: MEDLINE
    • Publication Information:
      Publication: 2008- : Oxford : Oxford Journals
      Original Publication: London, British Medical Assn.
    • Subject Terms:
    • Abstract:
      Aims: Cyclic adenosine monophosphate (cAMP) regulates cardiac excitation-contraction coupling by acting in microdomains associated with sarcolemmal ion channels. However, local real time cAMP dynamics in such microdomains has not been visualized before. We sought to directly monitor cAMP in a microdomain formed around sodium-potassium ATPase (NKA) in healthy and failing cardiomyocytes and to better understand alterations of cAMP compartmentation in heart failure.
      Methods and Results: A novel Förster resonance energy transfer (FRET)-based biosensor termed phospholemman (PLM)-Epac1 was developed by fusing a highly sensitive cAMP sensor Epac1-camps to the C-terminus of PLM. Live cell imaging in PLM-Epac1 and Epac1-camps expressing adult rat ventricular myocytes revealed extensive regulation of NKA/PLM microdomain-associated cAMP levels by β2-adrenoceptors (β2-ARs). Local cAMP pools stimulated by these receptors were tightly controlled by phosphodiesterase (PDE) type 3. In chronic heart failure following myocardial infarction, dramatic reduction of the microdomain-specific β2-AR/cAMP signals and β2-AR dependent PLM phosphorylation was accompanied by a pronounced loss of local PDE3 and an increase in PDE2 effects.
      Conclusions: NKA/PLM complex forms a distinct cAMP microdomain which is directly regulated by β2-ARs and is under predominant control by PDE3. In heart failure, local changes in PDE repertoire result in blunted β2-AR signalling to cAMP in the vicinity of PLM.
      (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: [email protected].)
    • References:
      Am J Physiol Regul Integr Comp Physiol. 2016 Jun 1;310(11):R1312-21. (PMID: 27147617)
      Biochem J. 1994 Dec 1;304 ( Pt 2):635-40. (PMID: 7999001)
      Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20756-61. (PMID: 23185013)
      Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11476-81. (PMID: 12169672)
      Circulation. 2002 Jul 23;106(4):447-53. (PMID: 12135944)
      J Biol Chem. 1991 Jun 15;266(17):11126-30. (PMID: 1710217)
      Am J Physiol Heart Circ Physiol. 2003 Jan;284(1):H225-33. (PMID: 12388273)
      Sci STKE. 2001 Oct 16;2001(104):re15. (PMID: 11604549)
      Acta Physiol (Oxf). 2013 Apr;207(4):650-62. (PMID: 23383621)
      IUBMB Life. 2009 Mar;61(3):215-21. (PMID: 19243007)
      J Biol Chem. 2013 May 10;288(19):13808-20. (PMID: 23532852)
      Cardiovasc Res. 2017 Jun 1;113(7):770-782. (PMID: 28505272)
      Nat Protoc. 2011 Apr;6(4):427-38. (PMID: 21412271)
      Clin Transl Sci. 2010 Aug;3(4):189-96. (PMID: 20718822)
      J Appl Physiol (1985). 2015 Sep 1;119(5):475-86. (PMID: 26159759)
      Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6854-9. (PMID: 19342485)
      Biochim Biophys Acta. 1957 Feb;23(2):394-401. (PMID: 13412736)
      J Am Coll Cardiol. 2013 Oct 22;62(17):1596-606. (PMID: 23810893)
      Physiol Rep. 2015 Aug;3(8):. (PMID: 26296772)
      Am J Physiol. 1977 May;232(5):C165-73. (PMID: 324293)
      Gene. 2001 Jun 13;271(1):69-79. (PMID: 11410367)
      J Biol Chem. 2004 Sep 3;279(36):37215-8. (PMID: 15231839)
      Am J Physiol Cell Physiol. 2009 Jun;296(6):C1346-55. (PMID: 19339511)
      J Mol Cell Cardiol. 2003 Jan;35(1):5-25. (PMID: 12623296)
      Cardiovasc Res. 2005 Jan 1;65(1):93-103. (PMID: 15621037)
      Circ Res. 2008 Aug 1;103(3):279-88. (PMID: 18599868)
      J Biol Chem. 2011 Oct 14;286(41):36020-31. (PMID: 21868384)
      Circ Res. 2003 Oct 17;93(8):700-9. (PMID: 14563709)
      Circ Res. 2012 Aug 3;111(4):482-92. (PMID: 22859670)
      J Biol Chem. 2004 Dec 10;279(50):52095-105. (PMID: 15466415)
      J Mol Cell Cardiol. 2015 Apr;81:34-45. (PMID: 25640161)
      Cardiovasc Res. 2014 Oct 1;104(1):72-82. (PMID: 25103111)
      J Biol Chem. 2005 Sep 2;280(35):31036-44. (PMID: 15961389)
      Science. 2010 Mar 26;327(5973):1653-7. (PMID: 20185685)
      Nat Commun. 2015 Apr 28;6:6965. (PMID: 25917898)
      Circ Res. 2006 Dec 8;99(12):1376-83. (PMID: 17095720)
      Circulation. 2008 Apr 8;117(14):1849-55. (PMID: 18362230)
      Circ Res. 2006 Nov 10;99(10):1084-91. (PMID: 17038640)
      Am J Physiol Renal Physiol. 2003 Jul;285(1):F121-9. (PMID: 12657562)
      Circ Res. 2015 Apr 10;116(8):1304-11. (PMID: 25688144)
      Drugs. 2003;63(5):439-52. (PMID: 12600224)
    • Grant Information:
      RG/12/18/30088 United Kingdom BHF_ British Heart Foundation; RG/17/13/33173 United Kingdom BHF_ British Heart Foundation; 109604/Z/15/Z United Kingdom WT_ Wellcome Trust; FS/14/68/30988 United Kingdom BHF_ British Heart Foundation; MR/L006855/1 United Kingdom MRC_ Medical Research Council; RG/17/15/33106 United Kingdom BHF_ British Heart Foundation
    • Contributed Indexing:
      Keywords: FRET; Heart failure; Phosphodiesterase; Phospholemman; cAMP
    • Accession Number:
      0 (Adrb2 protein, rat)
      0 (Adrenergic beta-Agonists)
      0 (Guanine Nucleotide Exchange Factors)
      0 (Membrane Proteins)
      0 (Phosphoproteins)
      0 (Receptors, Adrenergic, beta-2)
      135541-82-1 (phospholemman)
      E0399OZS9N (Cyclic AMP)
      EC 2.7.11.11 (Cyclic AMP-Dependent Protein Kinases)
      EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 2)
      EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 3)
      EC 3.6.1.- (Atp1a1 protein, rat)
      EC 7.2.2.13 (Sodium-Potassium-Exchanging ATPase)
    • Publication Date:
      Date Created: 20180831 Date Completed: 20200330 Latest Revision: 20211006
    • Publication Date:
      20240829
    • Accession Number:
      PMC6383061
    • Accession Number:
      10.1093/cvr/cvy221
    • Accession Number:
      30165515